APA (7th ed.) Citation

A, S., JC, T., A, A., A, N., C, H., Y, S., . . . F, W. (2021). Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. ClinicoEconomics and outcomes research : CEOR, 13, 789. https://doi.org/10.2147/CEOR.S310619

Chicago Style (17th ed.) Citation

A, Shah, Tosh JC, Ambavane A, Nikolaou A, Hogea C, Samyshkin Y, Gorsh B, Maiese EM, and Wang F. "Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States." ClinicoEconomics and Outcomes Research : CEOR 13 (2021): 789. https://doi.org/10.2147/CEOR.S310619.

MLA (9th ed.) Citation

A, Shah, et al. "Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States." ClinicoEconomics and Outcomes Research : CEOR, vol. 13, 2021, p. 789, https://doi.org/10.2147/CEOR.S310619.